MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 03-09-2026
Anixa Biosciences Operating Income 2011-2026 | ANIX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Anixa Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11.7 M | -13.8 M | -11 M | -13.9 M | -13.1 M | -9.98 M | -11.9 M | -14.3 M | -6.08 M | -4.51 M | -945 K | -5.04 M | -7.92 M | -4.13 M | -5.03 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -945 K | -14.3 M | -8.89 M |
Quarterly Operating Income Anixa Biosciences
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.72 M | - | -2.44 M | -3 M | -3.39 M | - | -3.59 M | -3.47 M | -3.61 M | - | -2.84 M | -2.56 M | -2.56 M | -10.3 M | -2.8 M | -3.59 M | -2.23 M | -9.06 M | -4.39 M | -2.44 M | -2.63 M | -7.74 M | -2.44 M | -2.67 M | -4.98 M | -9.76 M | -2.18 M | -2.59 M | -1.87 M | -8.88 M | -5.61 M | -1.4 M | -1.39 M | -4.34 M | -1.73 M | -1.21 M | -1.47 M | -3.6 M | -975 K | -1.15 M | 3.86 M | 233 K | -1.49 M | -2.13 M | -1.96 M | -3.48 M | -160 K | -1.36 M | -2.07 M | -6.14 M | -2.22 M | -1.85 M | -887 K | -2.41 M | -643 K | -878 K | -1.53 M | -4.02 M | -1.21 M | -1.29 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.86 M | -10.3 M | -2.9 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 13.65 | -0.44 % | $ 99.4 M |  Israel |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Bioventus
BVS
|
54 M | $ 8.87 | 2.9 % | $ 591 M | USA |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 151.97 | -2.34 % | $ 7.53 B | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 25.83 | 1.06 % | $ 717 M | USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 17.32 | 1.82 % | $ 923 M | USA |
 |
DexCom
DXCM
|
912 M | $ 66.34 | 3.27 % | $ 25.9 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | $ 103.85 | 0.27 % | $ 19.6 B | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M |  China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 14.95 | 1.22 % | $ 452 M | USA |
|
Biodesix
BDSX
|
-34.5 M | $ 17.29 | -3.3 % | $ 2.24 B | USA |
 |
Guardant Health
GH
|
-437 M | $ 87.18 | 1.98 % | $ 10.9 B | USA |
 |
Danaher Corporation
DHR
|
4.69 B | $ 191.39 | 2.17 % | $ 136 B | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 97.61 | -0.73 % | $ 8.05 B |  Irlanda |
 |
IQVIA Holdings
IQV
|
2.18 B | $ 164.89 | 0.1 % | $ 28.3 B | USA |
 |
Illumina
ILMN
|
-833 M | $ 119.28 | 0.29 % | $ 19 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 198.94 | -0.38 % | $ 22.1 B | USA |
 |
QIAGEN N.V.
QGEN
|
97.7 M | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
1.35 B | $ 111.83 | 0.28 % | $ 34 B | USA |
 |
BioNano Genomics
BNGO
|
-104 M | $ 1.11 | - | $ 1.41 M | USA |
 |
DarioHealth Corp.
DRIO
|
-56.2 M | $ 8.42 | -6.44 % | $ 239 M | Israel |
 |
Lantheus Holdings
LNTH
|
311 M | $ 78.5 | -1.25 % | $ 5.3 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
-42.7 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 453.64 | 0.72 % | $ 13.1 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Celcuity
CELC
|
-113 M | $ 114.9 | 0.6 % | $ 4.53 B | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 9.11 | 0.22 % | $ 1.98 B | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 17.4 | 5.33 % | $ 389 M | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 8.24 | 4.57 % | $ 1.06 B | USA |
 |
Invitae Corporation
NVTA
|
-94.9 M | - | - | $ 21.2 M | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
-541 M | $ 197.68 | 5.23 % | $ 19.5 B | USA |
 |
OPKO Health
OPK
|
-152 M | $ 1.19 | - | $ 826 M | USA |
 |
Pacific Biosciences of California
PACB
|
-554 M | $ 1.36 | 2.26 % | $ 408 M | USA |